Related Experiment Video
Updated: Jul 7, 2026
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Periprocedural anticoagulation for atrial fibrillation ablation
M Eyman Mortada1, K Chandrasekaran, Vikram Nangia
1Electrophysiology Laboratories of Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health-Milwaukee Clinical Campus, Milwaukee, Wisconsin 53215, USA.
Insights
Administering warfarin and aspirin without low molecular weight heparin is a safe anticoagulation strategy for atrial fibrillation (AF) ablation patients without LA thrombi. This approach minimizes stroke risk post-procedure.
Area of Science:
- Cardiology
- Electrophysiology
- Thrombosis Research
Background:
- Catheter ablation for atrial fibrillation (AF) carries risks of left atrial (LA) thrombi and stroke.
- Optimal anticoagulation strategies during AF ablation remain undetermined.
Purpose of the Study:
- To evaluate the safety and efficacy of using warfarin and aspirin without low molecular weight heparin (LMWH) in patients undergoing AF ablation.
Main Methods:
- 207 patients underwent AF ablation with transesophageal echocardiography (TEE) to rule out LA clot.
- Heparin was used during the procedure, followed by aspirin pre-ablation and warfarin post-ablation.
- Warfarin and aspirin were continued for 6 weeks; LMWH was administered only if LA smoke was detected on TEE.
Main Results:
- Two patients experienced transient ischemic attacks (TIAs) post-ablation, both with subtherapeutic international normalized ratios (INRs).
- No other major thromboembolic events were reported in the study cohort.
Conclusions:
- Administering aspirin pre-ablation and warfarin post-ablation, without LMWH, is a safe anticoagulation method for AF ablation patients without LA thrombi or smoke.
- Meticulous intraprocedural anticoagulation is crucial for this strategy's success.
Background:
Catheter ablation for atrial fibrillation (AF) can increase risk of left atrial (LA) thrombi and stroke. Optimal periprocedural anticoagulation has not been determined.
Objective:
We report the role of administering warfarin and aspirin without low molecular weight heparin in patients undergoing AF ablation.
Methods:
A total of 207 patients underwent ablation for AF. Transesophageal echocardiography (TEE) guided transseptal puncture and ruled out clot in the LA. After first puncture, the sheath was flushed with heparin (5,000 Units/mL). After second puncture, a bolus of 80 units/kg of heparin was given, followed by an infusion to maintain activated clotting time (ACT) around 300-350 seconds. Warfarin was stopped and aspirin was started (325 mg/day) 3 days preprocedure. Warfarin was restarted on the day of the procedure. Both medications were continued for 6 weeks postablation. Warfarin was continued for 6 months in patients with prior history of persistent or recurrent AF. Thirty-seven patients who showed smoke in the LA on TEE were given low molecular weight heparin postprocedure until international normalized ratio (INR) was therapeutic.
Results:
Thirty-two patients had persistent and 175 had paroxysmal AF; 87 were cardioverted during ablation. Two patients had transient ischemic attack (TIA) on the sixth and eighth days, respectively, following ablation, with complete recovery. Both had subtherapeutic INRs.
Conclusion:
In patients without demonstrable clot or smoke in the LA, starting aspirin 3 days prior and warfarin immediately post-radiofrequency ablation, without low molecular weight heparin, with meticulous anticoagulation during the procedure, appears to be a safe mode of anticoagulation.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:28Cardiac Catheterization I: Pre-Procedure Overview